Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Shubham Pant, MD, MBBS
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Ritu Salani, MD, MBA
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Justin Gainor, MD
Jacob Sands, MD
Managing Myelofibrosis-Associated Anemia
Gabriela Hobbs, MD
Real-World Experience With Pacritinib in the US
John Mascarenhas, MD
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
Improving Transfusion Independence With JAK Inhibitor Therapy
Managing Myelofibrosis-Associated Thrombocytopenia
Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
How and When to Manage Ruxolitinib Failure
Unresectable Hepatocellular Carcinoma: Selecting the Optimal First-Line ICI Combination
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.